The Health Resources and Services Administration should abandon its consideration of a 340B rebate model pilot program ...

New platform unifies data, automates workflows, and delivers predictive intelligence to help pharmacists and other health care providers maximize 340B performance, improve and accelerate patient ...

Hospitals and clinics told regulators that switching to rebates in the 340B drug discount program would impose costs that ...

Hospital and pharma groups have sharpened their spears for the rematch on 340B rebates.  | The administration's second stab ...

In February 2026, the Department of Justice filed amicus briefs supporting pharmaceutical manufacturers, asserting that Rhode ...

AHA urges HRSA to axe 340B model that would cost hospitals over $1 billion annually and increase administrative burdens.

A federal court has struck down a 12-year-old Health Resources and Services Administration policy that restricted how certain 340B hospitals could make initial drug purchases, finding that the agency ...

Hospitals across the US are declining to consent to an HHS survey of their prescription drug acquisition costs given the ...

AbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount ...

The 340B Drug Pricing Program must be reformed to better patient health and disincentivize institutional profit-seeking ...

While it may be hard to believe, there is one issue in Washington that meets the above criteria: fixing the 340B program.